Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from TuHURA Biosciences ( (HURA) ).
On November 22, 2025, TuHURA Biosciences, Inc.’s Shelf Registration Statement became effective, allowing the company to continue offering shares previously registered under a Resale Registration Statement. This development enables the selling securityholders to offer shares from time to time under the new registration, potentially impacting the company’s market operations and investor relations.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative bioscience solutions.
Average Trading Volume: 204,698
Technical Sentiment Signal: Sell
Current Market Cap: $96.88M
For an in-depth examination of HURA stock, go to TipRanks’ Overview page.